Back to Agenda
Global Regulatory Perspectives on Obesity as a Chronic Disease: Learnings from FDA, EMA, PMDA, CDE, and Beyond
Session Chair(s)
Jingyu (Julia) Luan, PHD
Executive Regulatory Science Director, BioPharmaceuticals R&D
AstraZeneca, United States
Chronic Disease Town Hall spotlights emerging programs and global initiatives for chronic disease drug development, outlines the current landscape, explores opportunities and challenges, and assesses strategies to boost efficiency and accelerate therapeutic innovation.
Learning Objective : Understand the present landscape, opportunities, and challenges of chronic disease drug development; Describe emerging programs and global initiatives designed to facilitate development of chronic disease drugs; Assess various considerations and strategies to enhance the efficiency of chronic disease drug development.
Have an account?